Browsing by Author "Turhan, Turan"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Publication Secretagogin may not be a new neuroendocrine biomarker in schizophrenia while levels may reflect clinical severity(Taylor & Francis Ltd, 2019-10-02) Erzin, Gamze; Topçuoğlu, Canan; Bayram, Şenol; Karadağ, Hasan; Turhan, Turan; Göka, Erol; Özkaya, Güven; 0000-0003-0297-846X; A-4421-2016OBJECTIVE: Schizophrenia is a neurodegenerative and neurodevelopmental disorder. For this reason, it is important to determine the level of markers that are neuroprotective and have been altered in other neurodegenerative diseases in inspecting the etiology of schizophrenia. Secretagogin (SCGN), is a member of Calcium (Ca) binding proteins and thought to have a neuroprotective effect. In this study, we aimed to compare the level of secretagogin (SCGN) between age and gender-matched schizophrenia and control group.METHODS: Fifty-three patients with schizophrenia who applied to outpatient clinics of our hospital and 37 healthy controls included in the study. Schizophrenia diagnoses of the patients were verified using the DSM-5 criteria. Serum secretagogin levels were measured with the enzyme-linked immunosorbent assay (ELISA) test. The Body Mass Index (BMI) of the patient group was measured.RESULTS: There was no significant difference between the controls and patients in terms of fasting blood glucose and insulin levels. We did not find any difference in terms of the levels of serum secretagogin between patients with schizophrenia and controls. Negative correlations were found between the level of secretagogin and PANSS positive score, PANSS negative score, PANSS general psychopathology score.CONCLUSION: There is increasing evidence that SCGN may play a role in central nervous system (CNS) activity. Future studies might help to explicitly present the relationship between secretagogin and schizophrenia.Item A short guideline on chronic kidney disease for medical laboratory practice(Walter de Gruyter, 2016-06-01) Abuşoğlu, Sedat; Aydın, İlknur; Bakar, Funda; Bekdemir, Tan; Gülbahar, Özlem; İşlekel, Huray; Pektaş, Macit; Pir, Kamil; Portakal, Oytun; Serdar, Muhittin; Turhan, Turan; Yücel, Doğan; Zengi, Oğuzhan; Özarda, Yeşim; Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; AAL-8873-2021Chronic kidney disease (CKD) is asymptomatic in the early stage. Kidney function might be lost 90% when the symptoms are overt. However, in case of early detection, progression of the disease can be prevented or delayed. If not detected it results in end stage renal disease. Therefore, the level of awareness about CKD should be increased. The role of medical laboratory is utmost important for the diagnosis and staging of CKD. In this paper, the main tasks of the laboratory specialists are described and the outlines are as follows. Creatinine assays should be traceable to internationally recognised reference materials and methods, specifically isotope dilution mass spectrometry. When reporting the creatinine result, eGFR should also be reported in adult (> 18 years) population. A warning expression should be included in the report form if eGFR result is <60 mL/min/1.73 m(2). eGFR values should be expressed quantitatively up to 90 mL/min/1.73 m(2) by CKD-EPI equation. Above 90 mL/min/1.73 m(2), eGFR values can be expressed quantitatively or >90 mL/min/1.73 m2. eGFR equations of the adult population should not be used for pediatric population. Different equations utilizing also patient height should be used. The enzymatic creatinine assay should be preferred. eGFR based on cystatin C can be used for confirmation in the pediatric population. Cystatin C measurements, at least when eGFR based on creatinine is not reliable and for confirmation should be encouraged. Proteinuria or albuminuria values should be measured in spot samples and reported in proportion to creatinine.